2019 ESMO Immuno-Oncology Congress | Supplements And Featured Publications

Pembrolizumab Benefit Not Altered by KRAS Status in Nonsquamous NSCLC

January 07, 2020

Two analyses presented at the 2019 ESMO Immuno-Oncology Congress provided data supporting pembrolizumab, either as monotherapy or in combination with chemotherapy, as a first-line treatment option in patients with nonsquamous non–small cell lung cancer, regardless of KRAS mutational status.

Safety of Frontline Durvalumab Combo Confirmed in Extensive-Stage Small Cell Lung Cancer

January 04, 2020

Few immune-mediated adverse events were observed with frontline durvalumab plus platinum-based therapy and etoposide in patients with extensive-stage small cell lung cancer, and no treatment-emergent antidrug antibodies were elicited by the PD-L1 inhibitor, according to an analysis of the phase III CASPIAN trial reported at the 2019 ESMO Immuno-Oncology Congress.

Frontline Nivolumab/Ipilimumab Shows Clinical Benefit in NSCLC With Poor Prognosis

January 04, 2020

First-line treatment with nivolumab combined with low-dose ipilimumab was safe and showed encouraging overall survival, regardless of PD-L1 expression, in patients with advanced non–small cell lung cancer, including those with comorbidities or poor ECOG performance status.

BL-8040 Plus Pembrolizumab/Chemo Provides Disease Control in Pancreatic Cancer

January 02, 2020

A triplet regimen of the CXCR4 antagonist BL-8040 plus pembrolizumab and standard chemotherapy showed promising antitumor activity in the second-line setting for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.

Frontline Nivolumab Combo Succeeds in Squamous NSCLC, But Misses OS Endpoint in Nonsquamous Histology

December 31, 2019

The first-line combination of nivolumab and platinum-based chemotherapy improved overall survival, progression-free survival, and objective response rate compared with chemotherapy in patients with squamous non–small cell lung cancer, but did not improve survival in those with nonsquamous disease.

High PD-L1 Expression, bTMB Effective Markers for Single-Agent Atezolizumab Benefit in NSCLC

December 29, 2019

PD-L1-high status, determined via 3 separate immunohistochemistry assays, and blood tumor mutational burden strongly favored atezolizumab over platinum-based chemotherapy and supports the PD-L1 inhibitor as a first-line treatment option in patients with advanced non–small cell lung cancer.